Full-Time

Head of IP Litigation

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

70% in-office structure.

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • J.D. from a national law school and admission to any state bar in the United States; eligible to register as in-house counsel in the State of Massachusetts.
  • A minimum of 15 years of experience in IP litigation, with a preference for global experience and a proven track record in the biotech/pharmaceutical industry.
  • Strong analytical, communication, and leadership skills, with the capability to build and lead a high-performing team.
Responsibilities
  • Drive the strategy for managing Moderna’s global IP litigation and opposition matters with an act with urgency approach, understanding the direct impact on Moderna’s mission and the patients we serve.
  • In collaboration with the SVP, Intellectual Property, develop a forward-looking, strategic approach to IP litigation, incorporating the mindset of pushing past possible to navigate the complexities of global intellectual property challenges.
  • Optimize the management of a diverse team of outside counsel, embodying the pivot fearlessly mindset by adapting strategies in response to evolving legal landscapes and business needs.
  • Ensure alignment with finance, corporate communications, and other key departments, demonstrating the remove viscosity mindset to facilitate smooth and informed decision-making processes.
  • Address discovery and litigation challenges with a focus on efficiency and minimal business disruption, applying the digitize everywhere possible mindset to leverage technology in streamlining processes.
  • Lead by example, fostering a culture of innovation, learning, and accountability within the IP team, demonstrating the obsess over learning and behave like owners mindsets to cultivate a high-performing team aligned with Moderna’s goals.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?